Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$248.80
-1.1%
$233.96
$160.36
▼
$261.00
$36.78B0.11.20 million shs197,682 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$51.54
-0.1%
$41.51
$23.62
▼
$59.97
$32.11B0.732.57 million shs1.40 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$95.53
-1.0%
$114.29
$61.22
▼
$134.00
$10.91B0.921.98 million shs388,078 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$161.93
-3.0%
$193.60
$67.86
▼
$224.31
$35.05B1.442.80 million shs660,591 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.69%-1.26%+8.17%+18.40%+50.19%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.39%-7.58%+39.38%+56.46%+70.42%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-3.76%-6.24%-20.80%-8.00%+37.80%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-3.15%-16.63%-6.23%-22.75%+146.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$248.80
-1.1%
$233.96
$160.36
▼
$261.00
$36.78B0.11.20 million shs197,682 shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$51.54
-0.1%
$41.51
$23.62
▼
$59.97
$32.11B0.732.57 million shs1.40 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$95.53
-1.0%
$114.29
$61.22
▼
$134.00
$10.91B0.921.98 million shs388,078 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$161.93
-3.0%
$193.60
$67.86
▼
$224.31
$35.05B1.442.80 million shs660,591 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
-0.69%-1.26%+8.17%+18.40%+50.19%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+0.39%-7.58%+39.38%+56.46%+70.42%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-3.76%-6.24%-20.80%-8.00%+37.80%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-3.15%-16.63%-6.23%-22.75%+146.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$254.411.10% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3.00
Buy$53.503.74% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.46
Hold$108.1812.11% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.92
Moderate Buy$262.7557.46% Upside

Current Analyst Ratings Breakdown

Latest HALO, RVMD, BIIB, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Reiterated RatingBuy$350.00
11/16/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy
11/13/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Lower Price TargetEqual Weight$57.00 ➝ $56.00
11/13/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Lower Price TargetOverweight$272.00 ➝ $247.00
11/11/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
DowngradeOverweight ➝ Equal Weight$105.00 ➝ $109.00
11/11/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
DowngradeStrong-Buy ➝ Hold
11/9/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
UpgradeHold (C+) ➝ Buy (B-)
11/9/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
UpgradeBuy (B) ➝ Buy (B+)
11/9/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingOverweight$245.00 ➝ $305.00
11/6/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
DowngradeOutperform ➝ Hold$110.00 ➝ $117.00
11/6/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Boost Price TargetMarket Outperform$93.00 ➝ $149.00
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.76$22.73 per share11.07$128.01 per share1.97
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B8.65$1.60 per share32.14$10.15 per share5.08
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B7.88$4.57 per share21.10($0.48) per share-201.04
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,116.78N/AN/A$11.10 per share15.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34107.5415.792.843.37%9.38%5.69%2/5/2027 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.1739.8032.432.0816.97%13.67%6.42%N/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.9324.559.850.3826.93%751.81%23.84%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$9.11N/AN/AN/AN/A-84.51%-51.97%N/A

Latest HALO, RVMD, BIIB, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.36$0.56+$0.20$0.5510$1.20 billion$1.19 billion
11/5/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.30$2.39+$0.09$2.01$491.63 million$492.97 million
11/4/2026Q3 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.35-$1.90+$0.45-$1.90$25.58 million$197.56 million
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.74
2.45
2.43
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
3.88
3.60
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.44
8.36
8.34

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423114.01 million111.16 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883216.29 million199.85 millionOptionable

Recent News About These Companies

What is HC Wainwright's Forecast for RVMD FY2026 Earnings?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Biogen stock logo

Biogen NASDAQ:BIIB

$248.80 -2.85 (-1.13%)
As of 11:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$51.54 -0.04 (-0.07%)
As of 11:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$95.52 -0.98 (-1.01%)
As of 11:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$161.93 -4.94 (-2.96%)
As of 11:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.